The Mutational and Microenvironmental Landscape of Cutaneous Squamous Cell Carcinoma: A Review

被引:0
作者
Hosseini, Tara M. [1 ]
Park, Soo J. [1 ,2 ]
Guo, Theresa [1 ,3 ]
机构
[1] Univ Calif San Diego, Gleiberman Head & Neck Canc Ctr, Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Dept Otolaryngol Head & Neck Surg, La Jolla, CA 92093 USA
关键词
skin cancer; cutaneous squamous cell carcinoma (cSCC); actinic keratosis (ak); genetic landscape; tumor microenvironment; mutations; TUMOR-ASSOCIATED MACROPHAGES; REGULATORY T-CELLS; GROWTH-FACTOR RECEPTOR; PHASE-II; PATHWAY ACTIVATION; METASTATIC HEAD; PLUS CETUXIMAB; TERT PROMOTER; RISK-FACTORS; SKIN;
D O I
10.3390/cancers16162904
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Cutaneous squamous cell carcinoma (cSCC) is a complex disease arising from an interplay of UV-induced DNA damage, genetic mutations, and alterations in the tumor microenvironment. While most cSCC cases can be treated with surgery, metastatic and locally advanced forms have a significantly worse prognosis and limited treatment options. The high mutational burden in cSCC makes it challenging to identify true driver alterations. Beyond genetics, the tumor microenvironment and its interaction with the immune system play a critical role in cSCC progression, evidenced by differences observed between immunocompromised and immunocompetent patients. In recent years, new therapeutic approaches have emerged, including immunotherapy and EGFR inhibitors, which have shown efficacy in treating advanced cSCC. Understanding the underlying mechanisms driving cSCC is crucial for developing novel and more effective therapies. This review aims to provide a comprehensive overview of the mutational landscape and microenvironmental factors in cSCC.Abstract Cutaneous squamous cell carcinoma (cSCC) manifests through the complex interactions of UV-induced DNA damage, genetic mutations, and alterations in the tumor microenvironment. A high mutational burden is present in cSCC, as well as both cSCC precursors and normal skin, making driver genes difficult to differentiate. Despite this, several key driver genes have been identified, including TP53, the NOTCH family, CDKN2A, PIK3CA, and EGFR. In addition to mutations, the tumor microenvironment and the manipulation and evasion of the immune system play a critical role in cSCC progression. Novel therapeutic approaches, such as immunotherapy and EGFR inhibitors, have been used to target these dysregulations, and have shown promise in treating advanced cSCC cases, emphasizing the need for targeted interventions considering both genetic and microenvironmental factors for improved patient outcomes.
引用
收藏
页数:22
相关论文
共 191 条
  • [1] Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma
    Aboul-Fettouh, Nader
    Morse, Daniel
    Patel, Jigar
    Migden, Michael R.
    [J]. DERMATOLOGY PRACTICAL & CONCEPTUAL, 2021, 11
  • [2] Radiotherapy combined with cetuximab for locally advanced head and neck cancer: Results and toxicity
    Acevedo-Henao, C. M.
    Valette, G.
    Miglierini, P.
    Lefur, E.
    Pradier, O.
    [J]. CANCER RADIOTHERAPIE, 2012, 16 (07): : 601 - 603
  • [3] Natural killer cells suppress human cutaneous squamous cell carcinoma cancer cell survival and tumor growth
    Adhikary, Gautam
    Heipertz, Erica L.
    Preradovic, Maja
    Chen, Xi
    Xu, Wen
    Newland, John J.
    Kaur, Navjot
    Vemuri, Mohan C.
    Eckert, Richard L.
    [J]. MOLECULAR CARCINOGENESIS, 2023, 62 (06) : 845 - 854
  • [4] Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies
    Al-Rohil, Rami N.
    Tarasen, Ashley J.
    Carlson, J. Andrew
    Wang, Kai
    Johnson, Adrienne
    Yelensky, Roman
    Lipson, Doron
    Elvin, Julia A.
    Vergilio, Jo-Anne
    Ali, Siraj M.
    Suh, James
    Miller, Vincent A.
    Stephens, Philip J.
    Ganesan, Prasanth
    Janku, Filip
    Karp, Daniel D.
    Subbiah, Vivek
    Mihm, Martin C.
    Ross, Jeffrey S.
    [J]. CANCER, 2016, 122 (02) : 249 - 257
  • [5] The Distinctive Features behind the Aggressiveness of Oral and Cutaneous Squamous Cell Carcinomas
    Alonso-Juarranz, Miguel
    Mascaraque, Marta
    Carrasco, Elisa
    Gracia-Cazana, Tamara
    De La Sen, Oscar
    Gilaberte, Yolanda
    Gonzalez, Salvador
    Juarranz, Angeles
    Falahat, Farzin
    [J]. CANCERS, 2023, 15 (12)
  • [6] Treatment of Advanced Cutaneous Squamous Cell Carcinomas with Epidermal Growth Factor Receptor Inhibitors
    Alter, M.
    Satzger, I.
    Mattern, A.
    Kapp, A.
    Gutzmer, R.
    [J]. DERMATOLOGY, 2013, 227 (04) : 289 - 294
  • [7] Anderson NM, 2020, CURR BIOL, V30, pR921, DOI 10.1016/j.cub.2020.06.081
  • [8] Understanding BRCA2 Function as a Tumor Suppressor Based on Domain-Specific Activities in DNA Damage Responses
    Andreassen, Paul R.
    Seo, Joonbae
    Wiek, Constanze
    Hanenberg, Helmut
    [J]. GENES, 2021, 12 (07)
  • [9] ARID2, AT-Rich Interaction Domain 2 Homo Sapiens (Human)-Gene-NCBI
  • [10] Skin Tumors Induced by Sorafenib; Paradoxic RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1
    Arnault, Jean Philippe
    Mateus, Christine
    Escudier, Bernard
    Tomasic, Gorana
    Wechsler, Janine
    Hollville, Emilie
    Soria, Jean-Charles
    Malka, David
    Sarasin, Alain
    Larcher, Magalie
    Andre, Jocelyne
    Kamsu-Kom, Nyam
    Boussemart, Lise
    Lacroix, Ludovic
    Spatz, Alain
    Eggermont, Alexander M.
    Druillennec, Sabine
    Vagner, Stephan
    Eychene, Alain
    Dumaz, Nicolas
    Robert, Caroline
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (01) : 263 - 272